Merck Reports Results From Phase 2b/3 Clinical Trial Evaluating Clesrovimab; Results From MK-1654-004 Trial Met All Prespecified Endpoints
Merck Reports Results From Phase 2b/3 Clinical Trial Evaluating Clesrovimab; Results From MK-1654-004 Trial Met All Prespecified Endpoints
默沙東報告了評估Clesrovimab的2b/3期臨床試驗結果； Mk-1654-004試驗結果符合所有預定的終點。
In the Phase 2b/3 trial, clesrovimab reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpoint) by more than 84% and 90%, respectively, through 5 months.
在2b/3期臨床試驗中，clesrovimab分別通過5個月以上降低了RSV相關住院率（次要終點）和RSV相關下呼吸道感染住院率（三級終點），分別超過84%和90%。
Clesrovimab has the potential to become the first and only approved immunization designed to protect infants with the same single dose regardless of weight for the duration of their first RSV season.
Clesrovimab有潛力成爲第一款也是唯一一款經批准的免疫設計，無論嬰兒體重如何，在他們的首個RSV季節中通過同一劑量保護。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間